RxDoctor Payments Data

Michael Nacol

Internal Medicine · Georgetown, TXNPI 1114915030

Payments from drug & device makers

$7,600in general payments, 2019–2025

Across 473 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$788
  • AstraZeneca$780
  • Novo Nordisk$773
  • Boehringer Ingelheim$665
  • Lilly USA, LLC$664
  • Amgen$595
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,54399%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,600 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$65,974
OzempicSemaglutide21$33,954
FarxigaDapagliflozin Propanediol14$16,335
SynthroidLevothyroxine Sodium28$1,998
Levothyroxine Sodium145$1,655
Ezetimibe36$1,130
Rosuvastatin Calcium74$1,109
Atorvastatin Calcium160$1,063
Telmisartan29$920
Gabapentin44$843
Irbesartan41$827
Finasteride55$745
Potassium Chloride28$710
Tamsulosin Hcl42$672
Bupropion XlBupropion Hcl21$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$665$65,97452 claims
Novo NordiskOzempic$773$33,95421 claims
AstraZenecaFarxiga$780$16,33514 claims
AbbVieSynthroid$513$1,99828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →